Table 2.

The effects of genetic polymorphism (-1291C/G) and clinical demographics on the MPH response

Independent variables	OR	95% CI	p-value
Gender	0.80	0.84–7.78	0.85
Age	0.92	0.62–1.37	0.69
BMI	1.33	0.99–1.78	0.05
Daily dose (mg/day)	1.01	0.93–1.10	0.68
Genotype
C/G vs. C/C	0.0001	0.0001–NA	0.99
G/G vs. C/C	0.0001	0.0001–NA	0.99

The subjects received MPH treatment were categorized as non-responders and responders and subjected to binary logistic regression analysis. Those with more than 25% reduction in the SNAPIV total scores were referred as responders. OR: odds ratio, CI: confidence interval, MPH: methylphenidate, BMI: body mass index, NA: not available, SNAP-IV: Swanson, Nolan and Pelham version IV